Slingshot members are tracking this event:

AbbVie's Main US Patent on HUMIRA (adalimumab) to expire in December 2016, Still Protected by Dozens of Other Patents

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details In December 2016, AbbVie's main US filed patent on HUMIRA will expire and allow for the generic manufacturing of the drug.  HUMIRA is AbbVie's most profitable product, accounting for 61% of total revenues in 2015.  However, AbbVie still has over 50 patents still protecting HUMIRA and sales shouldn't be affected until those expire in at least several years
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 31, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Patent Expiration, Humira